<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348449</url>
  </required_header>
  <id_info>
    <org_study_id>EC 211/17</org_study_id>
    <nct_id>NCT03348449</nct_id>
  </id_info>
  <brief_title>Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)</brief_title>
  <acronym>BIRDi</acronym>
  <official_title>A Retrospective Cohort Study of the Efficacy and Evolution of Comorbidities With the Combination of Raltegravir and Boosted Darunavir in Suppressed HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de las Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective cohort of virologically suppressed HIV-infected patients who received the
      combination of Raltegravir plus Darunavir boosted with cobicistat or ritonavir, as dual
      therapy, because or toxicity or intolerance to nucleoside analogues
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cohort study including those HIV-infected patients who received the
      combination of raltegravir plus darunavir boosted with cobicistat or ritonavir as dual
      therapy, due to the existence of toxicity or intolerance to nucleoside analogues, to
      evaluate:

        -  efficacy, measured as percentage of patients free of virological failure after 48 and 96
           weeks (ITT-e, snapchot analysis) and improvement in CD4+ count

        -  tolerance (rate of discontinuation and cause, and frequency of adverse events)

        -  evolution of different comorbidities (renal, bone, cardiovascular events)

      Patients will included if they have received at least 1 dose of the dual therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who maintained virological suppression on treatment at 48 weeks after using this dual therapy</measure>
    <time_frame>48 weeks</time_frame>
    <description>The number of patients who remained with virological suppression during the study at 48 weeks (ITT-exposed, snapchot analysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renal parameters at 48 weeks,for patients using dual therapy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluation of renal parameters in patients changing to this dual therapy, considering the previous use of TDF or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone parameters (bone mineral density by Dual X-ray absorptiometry) during the study</measure>
    <time_frame>48 weeks</time_frame>
    <description>Quantitative changes in bone mineral density (BMD) according to previous use of TDF and renal parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular risk (by using AHA score) for patients using dual therapy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in lipid parameters will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers during the study, measured by the CD4/CD8 ratio</measure>
    <time_frame>48 weeks</time_frame>
    <description>Those patients who received this dual therapy will be evaluated to determine changes in inflammatory biomarkers such as CD4/CD8 ratio</description>
  </secondary_outcome>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Comorbidities</condition>
  <condition>HIV/AIDS</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of data</intervention_name>
    <description>Outcome of patients will be collected from charts to evaluate primary and secondary objectives</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected patients with virological suppression but toxicity or intolerance to analogues
        who switched to the combination of Raltegravir plus boosted Darunavir
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Older than 18 years

          -  To have received the combination of raltegravir plus boosted darunavir in patients
             with virological suppression (more than 6 months) after toxicity or intolerance to
             nucleoside analogues

        Exclusion Criteria:

          -  Virological failure in the last 6 months previous to dual therapy

          -  Presence or suspicion of resistance to Darunavir (major mutations according to Meyer
             et al) or to Raltegravir (major mutations according to IAS list)

          -  Active hepatitis B
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose L Casado, MD, PhD</last_name>
    <phone>34913368672</phone>
    <email>jose.casado@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Casado, PhD</last_name>
      <phone>34913368672</phone>
      <email>jose.casado@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>José I Bernardino, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José L Blanco, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfonso Cabello, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Diaz de Santiago, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria I Espinosa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pepa Galindo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Garcia del Toro, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan C Lopez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alvaro Mena, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Montero, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenia Negredo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosario Palacios, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Vergas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asociacion para el Estudio de las Enfermedades Infecciosas</investigator_affiliation>
    <investigator_full_name>Jose L. Casado</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Dual therapy</keyword>
  <keyword>Comorbidities</keyword>
  <keyword>Nucleoside analogues sparing-regimens</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

